Vanda Pharmaceuticals Inc (VNDA) Stock
Key stats
- Market cap
- $250.95M
- Price / Earnings ratio
- -0.9x
- EPS (TTM)
- -$4.62
- Volume
- Loading
- 52-week high
- $9.94
- 52-week low
- $3.57
Source: third-party data provider, as of November 13, 2026
Compare with VNDA
Recent news
Vanda Pharmaceuticals Q3 Earnings Call Highlights
Vanda Pharmaceuticals Q3 Earnings Call Highlights
VNDA
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
VNDA
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
VNDA
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
VNDANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 49.81
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.22
- MACD histogram
- 0.06
- SMA 50
- $4.56
- Price below SMA 50
- EMA 50
- $4.45
- Price below EMA 50
- SMA 200
- $6.06
- Price below SMA 200
- EMA 200
- $5.73
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.04 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Vanda Pharmaceuticals Q3 Earnings Call Highlights
Vanda Pharmaceuticals Q3 Earnings Call Highlights
VNDAVanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates
VNDAVanda says anxiety drug failed main goal of late-stage study, puts program on hold
Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
VNDAVNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why
VNDA
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
VNDA
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
VNDA
Vanda Pharmaceuticals Q2 Earnings Call Highlights
Vanda Pharmaceuticals Q2 Earnings Call Highlights
VNDA
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
VNDA
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
VNDA
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
VNDANews tone: automated (AI) classification of the article's content, not a price prediction.
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Mihael H. Polymeropoulos M.D. | Founder, President, CEO & Chairman of The Board | 1960 |
| Mr. Kevin Patrick Moran | Senior VP, CFO & Treasurer | 1984 |
| Mr. Joakim Wijkstrom | Senior VP & Chief Marketing Officer | 1966 |
| Mr. Gunther Birznieks | Senior Vice President of Business Development | 1969 |
| Mr. Daniel Patrick McGuire | Senior VP, General Counsel & Secretary | — |
| Mr. Scott L. Howell | Chief People Officer | 1975 |
| Mr. Christos Polymeropoulos M.D. | Senior Vice President & Medical Director | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 49.81
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.22
- MACD histogram
- 0.06
- SMA 50
- $4.56
- Price below SMA 50
- EMA 50
- $4.45
- Price below EMA 50
- SMA 200
- $6.06
- Price below SMA 200
- EMA 200
- $5.73
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $15.00
- High
- $20.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.1 | -1.6 | ||||||||||
| 2022 | -8.4 | -25.3 | -0.4 | -16.1 | -3.8 | +11.8 | -3.7 | +0.4 | -8.6 | +3.5 | +2.5 | -32.6 |
| 2023 | +3.5 | -16.0 | +5.3 | -10.2 | -7.5 | +11.7 | -10.1 | -8.0 | -15.5 | +5.0 | -14.9 | +8.2 |
| 2024 | -20.4 | +19.8 | -10.8 | +15.5 | +7.1 | +10.4 | +4.7 | -6.2 | -7.7 | +2.4 | +10.5 | -5.0 |
| 2025 | -8.5 | +10.4 | -2.8 | +0.2 | -2.3 | +9.8 | -9.0 | +12.9 | +5.9 | -14.7 | +19.9 | +75.7 |
| 2026 | -8.6 | +15.1 | -15.4 | +0.4 | -7.9 | -3.9 | -15.7 | +3.3 | -9.4 | -21.2 | +7.0 |
